Cart
sales@molnova.com
Home - Products - Others - Other Targets - BLU0588

BLU0588

CAS No. 2810747-78-3

BLU0588( —— )

Catalog No. M35361 CAS No. 2810747-78-3

BLU0588 is a selective PRKACA inhibitor. BLU0588 inhibits PRKACA catalytic activity with a half-maximal inhibitory concentration (IC50) of 1 nM.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 296 Get Quote
5MG 426 Get Quote
10MG 625 Get Quote
25MG 908 Get Quote
50MG 1270 Get Quote
100MG 1701 Get Quote
500MG 3402 Get Quote
1G Get Quote Get Quote
Get Quotation Bulk Inquiry Add to Cart

Biological Information

  • Product Name
    BLU0588
  • Note
    Research use only, not for human use.
  • Brief Description
    BLU0588 is a selective PRKACA inhibitor. BLU0588 inhibits PRKACA catalytic activity with a half-maximal inhibitory concentration (IC50) of 1 nM.
  • Description
    BLU0588 is an orally active, potent and selective PRKACA (protein kinase cAMP-activated catalytic subunit alpha) kinase inhibitor, with an IC50 of 1 nM and dissociation constant (Kd) of 4 nM. BLU0588 can be used for fibrolamellar carcinoma (FLC) research.
  • In Vitro
    ——
  • In Vivo
    Animal Model:female NOD-SCID mice harboring FLC PDX tumors (6-8-week-old, FLC PDX shRNA cell lines or Hep3B cells were implanted)Dosage:30 mg/kg Administration:Orally, once daily, 34 days Result:Inhibited tumor growth in mice, by day 34 tumor growth was inhibited by 48.5%.
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Others
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2810747-78-3
  • Formula Weight
    423.51
  • Molecular Formula
    C26H25N5O
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 83.33 mg/mL (196.76 mM; Ultrasonic (<60°C)
  • SMILES
    O=C(N[C@@H]1C2=C(C=CC=C2)C[C@H]1N1CCCC1)C1=CC=C(C2=C3C=CNC3=NC=C2)N=C1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Stefanie S. Schalm, et al. Evaluation of Protein Kinase cAMP-Activated Catalytic Subunit Alpha as a Therapeutic Target for Fibrolamellar Carcinoma. Gastro Hep Advances. Volume 2, Issue 3, 2023, Pages 307-321.
Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog
related products
Sign In Join Free